Seeking New Horizons for Cancer Patients

Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients who are failing or resistant to current treatment regimens.

Learn How We are Making a Difference
Scroll down

Unlocking the Promise of Biology

Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.

View Our Academic Collaborations

Two Late-Stage Therapeutics for Multiple Oncology Indications with Unmet Medical Needs

VAL-083 is a structurally-unique small molecule targeting DNA to inhibit cancer cell replication and cell division, which leads to cell death. Like other established agents extensively studied by U.S. National Cancer Institute (NCI), such as cisplatin, paclitaxel and camptothecin, VAL-083 has been assessed in 42 Phase 1 and Phase 2 clinical trials sponsored by NCI.

REM-001 is a second generation photosensitizer drug possessing multiple advantages over earlier generation PDT compounds.

Learn More About VAL-083 View Our Ongoing Clinical Trials

Kintara Therapeutics, Inc.


Nasdaq: KTRA




Day Range

Year Range

Email Notifications

Sign Up